Caloric restriction and its mimetics in heart failure with preserved ejection fraction: mechanisms and therapeutic potential
Alexander Fuerlinger,
No information about this author
Alina Stockner,
No information about this author
Simon Sedej
No information about this author
et al.
Cardiovascular Diabetology,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: Jan. 18, 2025
Language: Английский
A Remotely Delivered, GLP-1RA-Supported Specialist Weight Management Program: 12 Month Outcomes From a Retrospective Service Evaluation (Preprint)
Published: Feb. 14, 2025
BACKGROUND
Limited
access
to
specialist
weight
management
services
(SWMS)
restricts
the
implementation
of
novel
obesity
pharmacotherapy
in
United
Kingdom’s
(UK)
National
Health
Service
(NHS).
Remote
delivery
GLP-1
receptor
agonist
(GLP-1RA)
medication
with
digital
behavioural
support
could
provide
a
scalable
solution,
but
evidence
for
long-term
effectiveness
is
limited
OBJECTIVE
To
evaluate
effectiveness,
feasibility,
acceptability
and
potential
cost-effectiveness
Second
Nature's
remotely-delivered,
semaglutide-supported
program
over
12
months
METHODS
Retrospective
data
were
extracted
participants
who
initiated
intervention
between
September
December
2023.
Primary
outcome
was
change
at
months.
Secondary
outcomes
included
behavioral
changes,
side
effects,
engagement,
participant
experience
comparative
cost
analysis
against
NHS
SWMS.
Descriptive
statistics
paired
two-tailed
t-tests
evaluated
outcomes.
Content
used
qualitative
data.
RESULTS
Of
341
(82.8%
women;
mean
age
49.0
years,
SD
11.1;
baseline
BMI
37.9
kg/m²,
6.9).
Participants
active
subscriptions
(39.6%,
n=135)
achieved
20.0
kg
(19.1%,
,P<.001)
loss
versus
12.4
(11.9%)
inactive
subscriptions.
Overall,
77.7%
≥10%
61.5%
≥15%.
Program
engagement
declined
from
113
(SD
78.4)
home
screen
views
month
1
25
29.06)
12.
Side
effects
decreased
time,
69.6%
reporting
none
by
Most
reported
positive
(34.2%)
or
neutral
(56.7%)
experiences
The
costs
estimated
30-40%
current
SWMS,
projecting
savings
£1.5m-£1.8m
per
100,000
population
CONCLUSIONS
This
evaluation
suggests
that
remotely-delivered
GLP-1RA-supported
can
be
effective,
feasible,
acceptable
cost-effective
people
living
obesity.
Further
research
within
public
healthcare
settings
needed
clinical
assess
sustained
results
continuation
discontinuation
medication.
Language: Английский
Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
Obesities,
Journal Year:
2025,
Volume and Issue:
5(2), P. 26 - 26
Published: April 18, 2025
Obesity
represents
a
global
health
challenge,
with
critical
and
urgent
need
for
long-term,
sustainable
management
strategies.
Tirzepatide
is
novel
dual
glucose-dependent
insulinotropic
polypeptide
(GIP)
glucagon-like
peptide-1
(GLP-1)
receptor
agonist.
At
first
approved
the
treatment
of
type
2
diabetes
mellitus,
tirzepatide
one
latest
clinically
commercially
available
pharmacological
options
obesity
management.
This
narrative
review
aimed
to
synthesize
existing
clinical
evidence
on
efficacy
safety
in
non-diabetic
obese
individuals.
A
comprehensive
literature
search
was
conducted
using
PubMed,
Scopus,
Web
Science,
ClinicalTrials.gov,
Google
Scholar
databases
identify
relevant
trials,
meta-analyses,
original
studies
assessing
weight-loss
impact
from
2022
onwards.
Synthesized
indicated
that
achieved
up
20.9%
weight
loss
over
72
weeks
(SURMOUNT-1),
18.4%
after
lifestyle
intervention
(SURMOUNT-3),
17.5%
Chinese
adults
(SURMOUNT-CN),
25.3%
continued
88
(SURMOUNT-4).
Meta-analyses
confirmed
higher
odds
≥5–20%
versus
semaglutide
liraglutide,
significantly
reducing
body
mass
index,
waist
circumference,
blood
pressure,
atherosclerotic
cardiovascular
disease
risk.
Health-related
quality
life
improved
greater
loss,
gastrointestinal
side
effects
(nausea,
diarrhea,
constipation)
were
common
but
mild
moderate,
<5%
discontinuation.
significant
cardiometabolic
benefits,
individuals,
further
research
needed
long-term
efficacy,
safety,
application.
Language: Английский
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
World Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
31(4)
Published: Dec. 30, 2024
This
article
comments
on
the
work
by
Soresi
and
Giannitrapani.
The
authors
have
stated
that
one
of
most
novel
promising
treatments
for
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
use
glucagon-like
peptide
1
receptor
agonists,
especially
when
used
in
combination
therapy.
However,
despite
their
notable
efficacy,
these
drugs
were
not
initially
designed
to
target
MASLD
directly.
In
a
groundbreaking
development,
Food
Drug
Administration
has
recently
approved
resmetirom,
first
treatment
specifically
aimed
at
reducing
fibrosis
metabolic-associated
steatohepatitis.
Resmetirom,
an
orally
administered,
liver-directed
thyroid
hormone
beta-selective
agonist,
acts
directly
intrahepatic
pathways,
enhancing
its
therapeutic
potential
marking
beginning
new
era
MASLD.
Furthermore,
integration
lifestyle
modifications
into
management
essential
component
should
be
considered
reinforced.
By
incorporating
dietary
changes
regular
physical
exercise
treatment,
patients
may
achieve
improved
outcomes,
need
pharmacological
interventions
and/or
improving
efficacy.
As
complement
medical
therapies,
factors
overlooked
broader
strategy
managing
Language: Английский